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VOL. 103 NO. 1 / JANUARY 2015BISPHENOL A IS A TYPICAL
ENDOCRINE-DISRUPTING
CHEMICAL
The ﬁeld of environmental health
emerged historically from the observa-
tion of the decreased reproductive suc-
cess of wildlife populations in relation
to industrial chemicals (1). The concept
of endocrine-disrupting chemicals
(EDCs) was then proposed after various
reproductive functionalterations inwild-
life and humanswere linked to the inten-
sive use of pesticides in agriculture (2).
Thus, reproduction has a central place
in the EDC ﬁeld. One of the most studied
EDCs is bisphenol A (BPA; 2,2-bis11
VIEWS AND REVIEWS(4-hydroxyphenol) propane). A survey of the Pubmed database
with the use of ‘‘bisphenol A’’ or ‘‘BPA’’ as keywords provided
more than 10,000 articles published up to August 2014,
including clinical, epidemiologic, and experimental studies.
Moreover, BPAplayedand still has amajor role in the emergence
of new concepts in the EDC ﬁeld.
BPAwasﬁrst synthesized by Dianin in 1891, and its estro-
genic activity was discovered in 1936 (3). It is therefore one of
the oldest synthetic compounds known for its endocrine activ-
ity, although diethylstilbestrol (DES) has stronger estrogenic
activity. In the 1950s, it was observed that BPA could be poly-
merized to make polycarbonate plastic, a miraculous cheap
product that is lightweight, transparent, colorable, resistant
to impact, heat, and chemicals, inalterable with time, and
easy to mold and thermoform. BPA rapidly became one of
the most produced and used chemicals worldwide, even
though it was a recognized synthetic estrogen. About 70% of
BPA production (3.4 million tons per year) is used to produce
polycarbonate plastics used in a variety of common products
(optical, media, automotive, electrical and electronics, house-
wares and appliances, construction, medical, packaging,
etc.). About 20% of BPA is used as an essential component
of epoxy resins that are mainly used to coat the inner surface
of food and beverage metallic cans. Finally, BPA is used as
antioxidant or inhibitor of polymerization in some plasticizers,
polyvinyl chloride, and thermal cash register paper.
BPA can leach from food or beverage containers and is then
ingested. This is the main source of contamination, although its
ubiquitous distribution leads also to contamination through the
skin, especially in the case of thermal paper (4), or via inhalation
of householddusts. Its concentration inhuman serum is amatter
of debate, because biomonitoring and kinetic studies have
reached seemingly conﬂicting conclusions (5). Most studies
based on the analysis of blood samples from adults found that
the concentration of unconjugated BPA, which is the biologi-
cally active form, ranges from 0.2 to 10 ng/mL (0.9–44 nmol/L),
with an average concentration of 1–3 ng/mL (4–13 nmol/L)
(6–8). However, one study reported that unconjugated BPA
represents no more than 2% of the total BPA in blood,
leading to a plasma concentration of unconjugated BPA
<0.02 ng/mL (<0.1 nmol/L) (9). No data are presently
available on the BPA concentration in the plasma of human
fetuses during the ﬁrst trimester of pregnancy. BPA
quantiﬁcation in amniotic ﬂuid and in umbilical cord blood
samples during the second and the third trimesters of
pregnancy reported a mean level of 1 ng/mL (4.3 nmol/L)
with large interindividual variations (10). Furthermore, BPA
might particularly accumulate in early fetuses because of
lower metabolic clearance or conjugation at that
development stage (11).
BPA has been associated with many human diseases, such
as diabetes, obesity, cardiovascular, chronic respiratory and
kidneydiseases, breast cancer, behavioral troubles, toothdevel-
opmental defects, and reproductive disorders in both sexes
(12–14). Considerable research effort on BPA toxicity during
the last decades played a major role in raising two major
concepts in the EDCﬁeld: low-dose effects (i.e., effects observed
for concentrations in the range of human exposure) and non-
monotonicity (i.e., nonlinear relationship between dose and12effect, where the slope of the curve changes sign somewhere
within the range of the examined doses) (reviewed in 12, 15).
Importantly, BPA appears to be one of the EDCs that most
frequently shows a nonmonotonic dose-response curve (16).FETAL TESTIS IS A MAJOR TARGET OF
ENDOCRINE DISRUPTORS
One of the most studied functions in the EDC ﬁeld is male
reproduction. Many studies indicate that the incidence of
male reproductive function abnormalities in humans has
been increasing over the years (17–20). A decline in sperm
quality was the ﬁrst reported alteration (21) and was largely
debated. Among the different papers dealing on this issue,
published from 1995 up to now and including more than
1,000 participants, 16 found an unambiguous decline in
sperm count, whereas ten reported no change and three an
increase (22). A recent work showed that sperm
concentration in France has been declining by 1.9% per
year from 1996 to 2005 (23). It is now generally admitted
that, despite geographic variations in semen quality, a
global decrease in sperm count has occurred over the past
ﬁve decades (24). Moreover, the incidence of testicular
cancer, which is the most prevalent cancer in young men,
has been steadily increasing in all studied countries. For
example, it rose from 4 per 100,000 in 1960 to 10 per
100,000 in 2000 in Denmark (25). Finally, although the
incidence of cryptorchidism and hypospadias shows large
geographic variations (2%–9% and 0.2%–1% of male
newborns, respectively), increasing trends have been
reported in several countries (26).
In 1993, Sharpe and Skakkebaek hypothesized that EDCs,
particularly EDCs with estrogenic effects, could be one of the
causes of these disorders (27). This hypothesis has been
strengthened by much epidemiologic, clinical, and experi-
mental data over the years (18, 20, 28–31).
According to the ‘‘testis dysgenesis syndrome’’ (TDS)
hypothesis, reduced sperm count, testicular cancer, hypospa-
dias, and cryptorchidism result from defaults in testis develop-
ment during fetal life (32, 33). Speciﬁcally, the higher
occurrence of hypospadias and cryptorchidism may result
from alterations of the function of fetal Leydig cells. Indeed,
Leydig cells produce testosterone that is responsible for the
masculinization of the male urogenital system and external
genitalia (26, 34–37). An important ﬁnding in relation to the
TDS hypothesis is that androgens must act before the
phenotypic masculinization (38, 39). A reduction of
testosterone synthesis or action between 15.5 and 18.5 days
after conception (dpc) causes masculinization defects, such as
hypospadias, cryptorchidism, incomplete development or
agenesis of prostate and seminal vesicles, and reduction of
the anogenital distance (AGD) and penis length in male rat
fetuses, in which morphologic masculinization begins only at
18.5 dpc. It was therefore concluded that, in the rat, the
development of genitalia is programmed between 15.5 and
18.5 dpc, a period that was named the ‘‘masculinization
programming window’’. If such a window exists in other
species, it would be between 13 and 17.5 dpc in the mouse
and between the 6.5th and 14th gestational weeks (GW) inVOL. 103 NO. 1 / JANUARY 2015
FIGURE 1
Chemical structures of bisphenols A, S, and F.
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reproductive disorders and the ﬁnding that EDC effects are
often more severe when exposure occurs during fetal life
than in adulthood (40, 41) suggest the fetal testis as the main
EDC target.
BPA AFFECTS FETAL TESTIS DEVELOPMENT
Many studies have shown that, in rodents, exposure to high or
low doses of BPA during intrauterine life induces a range of
adverse effects in adult testes, including decreased sperm
count, DNA damage, and reduced sperm mobility. Although
a few experimental works did not observe such effects, the
negative effect of fetal exposure to BPA on adult spermato-
genesis is highly probable, and a decrease in fertility was
observed in the rat (15, 42, 43). Furthermore, perinatal
exposure to environmentally relevant doses of BPA induces
multigenerational impairments of male fertility (44).
Conversely, the existence of a negative effect of BPA on
fetal Leydig cell function or development is more debatable.
In the rat, one paper reported a reduction of the AGD (an in-
dex of testicular testosterone production) in male pups after
gestational gavage with 250 mg/kg/d BPA, but not with lower
or higher doses (2.5, 25, and 1,000 mg/kg/d) (45). However,
three other independent studies did not ﬁnd any effect of fetal
BPA exposure via maternal gavage with 1–50,000 mg/kg/
d (46–48). This was conﬁrmed by a more recent publication
showing that 50 or 1,000 mg/kg/d BPA given to pregnant
mice did not affect the AGD in the male offspring (49).
Moreover, very high doses of BPA, that are not relevant to
environmental exposure, were required to reduce rat fetal
testosterone production (50). Conversely, in humans, most
studies highlighted an association between masculinization
defects and BPA exposure during fetal life. In China, sons
of workers who were occupationally exposed to BPA during
pregnancy showed shorter AGD (51). In the general Korean
population, BPA level in the plasma of newborn boys with
hypospadias was seven times higher than in newborns
without hypospadias, and the difference was statistically
signiﬁcant (52). Finally, although no BPA increase was ﬁrst
detected in newborn boys with undescended testes in
France (10), recent data from this group showed a negative
correlation between the cord blood concentrations of BPA
and insulin-like 3 (INSL3) (53). INSL3 governs the transabdo-
minal descent of fetal testes from their initial mesonephrotic
position to the entrance of the inguinal duct (54). We recently
partly elucidated these species-speciﬁc discrepancies by
comparing the direct effect of BPA on fetal Leydig cell func-
tion in rat, mouse, and human testis explants. With the use of
an organotypic culture system (fetal testis assay [FeTA]) that
we developed previously (55–57), we demonstrated that
concentrations of BPA as low as 10 nmol/L (2.28 ng/mL)
reduce the fetal Leydig cell–speciﬁc functions in human
fetal testes, but at least 100-fold higher concentrations are
required in mouse and rat testes (58).
NEW CHALLENGES ARE RAISED BY BPA
During recent years, BPA regulation has been tightened, partic-
ularly to protect against exposureduring fetal andneonatal life.VOL. 103 NO. 1 / JANUARY 2015For example, BPA was banned in baby bottles in Canada in
2008, in France in 2010, and in the European Union in 2011.
The current tolerable dose intake (TDI) is 25 mg/kg/d in Canada
and 50 mg/kg/d in Europe. Recently, the French National
Agency for Safety in Food, Environment, andWork and the Eu-
ropean Food Safety Authority have recommended lowering
BPA TDI to 0.1 and 5 mg/kg/d, respectively. Finally, in France,
a law will forbid the use of BPA in any food or beverage pack-
aging from January 2015. Therefore, there is an urgent need to
ﬁnd alternatives to BPA for several industrial applications,
because BPA is about to be withdrawn from the market.
BPS (2,2-bis [4-hydroxyphenol]sulfone) and BPF (2,2-bis
[4-hydroxyphenol]methane) are presently not regulated and
are used without restriction. However, BPA-like effects can
be hypothesized because their chemical structures are similar
(Fig. 1). Toxicological data on BPS and BPF are scarce and no
in vivo or ex vivo study has evaluated their effects on any
physiologic function in humans or other mammals. One of
the aims of the present paper is to bring original data to
help address this deﬁciency.HOW TO ASSESS THE HAZARD OF
BISPHENOLS A, S, AND F?
Choice of in Vitro Method
In vitro approaches are simple, fast, and cheap methods to
investigate the direct effects of chemicals on fetal testis devel-
opment and function. They allow reducing the number of
killed animals and are an ethically and acceptable way to
experiment in humans. They also allow rigorous comparisons
between animal models and human samples.
In the 1990s, we started to develop an organotypic culture
approach that preserves the testis architecture and intercellular
communications. We obtained the best functional and histo-
logic results by placing rat fetal testis explants on amembrane
that ﬂoats on the culture medium, at the interface between air
and medium (55). This procedure allows maintaining in vitro
the development of Leydig cells (55), gonocytes (59), and Ser-
toli cells (60).We then adapted this methodology to the culture
of mouse (61, 62) and human (63, 64) fetal testes and named it
r/m/hFeTA (rat/mouse/humanFetal Testis Assay). Thismethod
was further validated in the present study by showing that the
expression of fetal Leydig cell–speciﬁc genes (Star, Hsd3b1,
Cyp17a1, Cyp11a1, LH/CG receptor, Insl3) measured by
means of quantitative polymerase chain reaction (qPCR)
assay, was maintained in r/mFeTA model (data not shown).
FeTA strengths and limits have been previously detailed (56).
Brieﬂy, this method allows the precise study of the kinetics13
VIEWS AND REVIEWSand duration of action of speciﬁc controlled concentrations of
a given compound or mixture of compounds in a deﬁned
medium. Treated testis explants are compared with control
explants (vehicle alone). Control and treated explants come
from the same testis (when fetal testes are large enough to be
cut into several pieces, for example in the case of human or
late fetal rodent testes) or from the contralateral testis of the
same fetus (for 14.5–15.5-dpc rat and 12.5–13.5-dpc mouse
fetuses). This paired analysis limits individual variability and
increases the method sensitivity. Finally, FeTA is largely less
time, money, and labor consuming than in vivo approaches.
Like any model, FeTA has inherent limits as well. The main
disadvantage is that long-term effects cannot be studied in
this system, because testes can develop in vitro only for a
few days (4–10 days, depending on the species, developmental
stage, and the studied end point). Another drawback is that the
FeTA approach allows studying only the direct effect of a
compound without taking into account the potential extrates-
ticular feedback loops or actions that could compensate or
affect the effects of exogenous chemicals.Choice of the Age at Explantation
Using this culture system, we often observed clear age-related
changes in fetal testis responsiveness to various compounds.
For example, GnRH, a putative paracrine testicular factor,
does not have any effect on testosterone secretion in 14.5-
dpc rat testes, whereas it has negative effects in 16.5–18.5-
dpc rat testes and positive effects in testis explants from
20.5 dpc onwards (55). Estradiol and DES reduce testosterone
production in 14.5-dpc rat testis explants but not in older
specimens (65). Therefore, it is necessary to choose a similar
developmental stage when comparing the effect of a com-
pound in different species. We can use human fetal testes
from abortions carried out between the 6th and the 12th
GW, a period when testosterone secretion and the number
of Leydig cells are increasing (66, 67). A comparable
developmental stage is 14.5 dpc in the rat (68) and 12.5 dpc
in the mouse (62). Interestingly, these stages correspond to
the masculinization programming window (38, 39).Choice of the Culture Conditions
A key question when evaluating the effect of a compound on
fetal Leydig cells using a culture approach is whether this
must be done in basal or stimulated conditions (i.e., in the
absence or presence of LH or placental chorionic gonado-
tropin [pCG]). pCG is abundantly secreted during the early
stages of human pregnancy; conversely, its expression and
activity are not detected in rat and mouse embryos (69–72).
In vivo, human fetal testes are stimulated by pCG, so it
would seem appropriate to add hCG in the culture medium.
However, hCG plasma concentrations change during
development and can vary considerably from one fetus to
another (73), thus making difﬁcult the reproduction of these
in vivo conditions. Stimulation with LH allows the
evaluation of the maximal steroidogenic capacity, whereas
basal testosterone secretion reﬂects the testis activity.
In vivo and in vitro experiments have shown that the14assessment of a compound in basal or stimulated conditions
can lead to very different results. For example, ex vivo
testosterone secretion by testes from 21.5-day-old rat fetuses
that were decapitated in utero 3 or 5 days earlier (a surgical
operation that suppresses pituitary LH production and is
compatible with embryo survival) was reduced in basal but
not in LH-stimulated conditions (74, 75). In vitro, exposure
to GnRH increased the basal and reduced the LH-stimulated
testosterone secretion by cultured rat fetal testes (55). Similar
results were obtained with phthalates in mouse fetal testes
(76). Moreover, basal testosterone secretion by rat fetal testes
following in utero exposure to diethylhexyl phthalate (DEHP)
can be inhibited by DEHP doses much lower than those
needed to inhibit hCG-induced testosterone production (77).
Here, we compared basal and LH-stimulated testosterone
secretion by rat, mouse, and human fetal testes explanted at
comparable developmental stages (14.5 dpc, 12.5 dpc, and
6.3–11.1 GW, respectively) and cultured with the use of the
FeTA system for 3–4 days (Fig. 2). Basal secretion rate is pre-
sented in Figure 2A.With rat andmouse testes, it increased for
2–3 days and was maintained or decreased thereafter. With
human fetal testes, the average of daily basal secretion pro-
gressively decreased throughout the culture but individual
evolution changed as a function of the developmental stage
(63, 64). The ability to respond to LH was higher in rodents
than in human, and LH-stimulated testosterone secretion
rate increased throughout the culture in the rat testes whereas
it was stable in the mouse and human testes (Fig. 2B). These
results can be explained by the fact that, as in vivo, each fetal
Leydig cell secretes less and less testosterone as a function of
the time (62). The species differences in the pattern of evolu-
tion of secretion could be explained by the changes in the
number of Leydig cells per testis in culture. Indeed, as
in vivo, the number of Leydig cells that differentiated during
the culture is lower in the mouse than in the rat (62). We did
not measure the number of Leydig cells in human fetal testes
during the culture. Nevertheless, any increase in their number
during the culture time should be very limited, because 3–
4 days is a short period compared to the 8 weeks during which
human Leydig cells expand in vivo during pregnancy (66, 67).
In conclusion, the species differences observed here in the
proﬁle of basal and LH-stimulated testosterone secretion in
culture are likely to be the consequence of intrinsic species
differences in the rate of Leydig cell proliferation and differ-
entiation. Thus, differences between species in the response to
one chemical compound observed using the FeTA system can
not be attributed to differences in the capacity of this in vitro
system to sustain functional Leydig cells.
Using the FeTA system, we previously reported that basal
testosterone secretion by human testes was not affected by
10,000 nmol/L DES, but it was reduced by concentrations as
low as 10 nmol/L of BPA. Conversely, 10 nmol/L and
100 nmol/L BPA did not affect testosterone secretion by
bothmouse and rat testes, and 10,000 nmol/L BPAwas needed
to observe a signiﬁcant reduction (58). Here, we conﬁrmed and
extended these results by showing that 1,000 nmol/L BPA
signiﬁcantly reduced basal testosterone secretion by human
and mouse fetal testes (Fig. 3A). Thus, in basal conditions,
the lowest observed adverse effect level is 100-fold higher inVOL. 103 NO. 1 / JANUARY 2015
FIGURE 2
In vitro testosterone secretion by control rat, mouse, and human fetal
testes. Fetal testeswere collected from pregnant rat at 14.5 days post-
conception (dpc), andmouse at 12.5 dpc as previously described (60).
Human testes were isolated from fetuses legally aborted during the
ﬁrst trimester of pregnancy (from 6.3 to 11.1 gestational weeks
[GW], mean 8.6  SEM 0.3 GW) at the Department of Obstetrics
and Gynecology, Antoine Beclere Hospital, Clamart (France) as
previously described (63), after obtaining written informed consent
for the scientiﬁc use of the fetuses. None of the terminations was
done for reasons of fetal abnormality. The project was approved by
the local Medical Ethics Committee and by the French Biomedicine
Agency (reference no. PFS12-002). Fetal testes were cultured with
the use of the fetal testis assay system, a method in which the
explants are placed on Millicell-CM Biopore membranes (Millipore)
ﬂoating on 320 mL phenol red–free Dulbecco modiﬁed Eagle
medium/Ham F12 (1:1) supplemented with 80 mg/mL gentamicin
without addition of any exogenous signaling factor (55, 56, 62,
63). Culture medium was completely changed every 24 hours. A
whole mouse or rat testis was put on the membrane, whereas
human testes were cut into small pieces owing to their larger size
and 3–4 pieces/testis were randomly placed on the membrane.
Explants were always cultured (A) without LH the ﬁrst day (D0) and
then without (basal conditions) or (B) with 100 ng/mL LH from
human pituitary (R5,000 IU/mg; Sigma; LH-stimulated conditions)
for the 3 subsequent days (D1 to D3). The daily amount of
testosterone secreted in the culture medium was measured in
duplicate by radioimmunoassay as previously described (68). The
limit of detection was 8 pg/100 mL. The intra-assay and interassay
coefﬁcients of variation were 2% and 5%, respectively. The daily
Eladak. BPS and BPF are not safe BPA alternatives. Fertil Steril 2015.
FIGURE 2 Continued
testosterone secretion at D1 to D3 was divided by the D0 secretion of
the same sample to obtain the relative testosterone secretions shown
in the ﬁgure. Values are shown as the mean  SEM of 14 rat, 102
mouse, and 27 human fetal testes in basal conditions and 22 rat,
24 mouse, and 10 human fetal testes in LH-stimulated conditions.
Values of the amounts of testosterone secreted at D0 were 51  4
(n ¼ 36) and 38  3 (n ¼ 126) pg/testis/h for rat and mouse testes,
respectively. For human testes, secretion at D0 changed
considerably as a function of time. Values, expressed as pg/testis/h,
were 133  17 at 6.5–7.4 GW (n ¼ 7), 1,966  221 at 7.5–
8.4 GW (n ¼ 14), 5,808  685 at 8.5–9.4 GW (n ¼ 8), and 12,677
 1,950 at 9.5–11.1 GW (n ¼ 8). Because bisphenol A (BPA) can
be leached in the medium from the plastic culture material (96), we
previously checked that the BPA concentration remained
undetectable in control medium at the end of the culture.(58)
Eladak. BPS and BPF are not safe BPA alternatives. Fertil Steril 2015.
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Fertility and Sterility®mouse than in human testes and 100- or 1,000-fold higher in
rat than in human testes. We also evaluated the effects of BPA
on LH-stimulated testosterone secretion (Fig. 3B). In the pres-
ence of 100 ng/mL LH, a concentration that induces the
maximum steroidogenic response (78), the inhibitory effect
of BPA in human testes was much less pronounced than in
basal conditions. Indeed, only 10,000 nmol/L BPA (and not
all the concentrations equal or up 10 nmol/L BPA as in basal
conditions; Fig. 3A) signiﬁcantly reduced testosterone secre-
tion. This is in accordance with recent results presented at
the 18th European Testis Workshop (79). Thus, the maximum
capacity to produce testosterone in response to LH is probably
not affected by environmental concentrations of BPA in hu-
man. Conversely in rat fetal testes, 10 nmol/L BPA had a sig-
niﬁcant effect in the presence of LH. Similarly, Akingbemi
et al. reported that 0.01 nmol/L BPA, but not higher doses,
decreased LH-stimulated testosterone production by adult
rat Leydig cells in culture, and that this effect was not present
in basal conditions (80).
In conclusion, the FeTA method in basal conditions is
more sensitive for testes from human and mouse but not
from rat, because addition of LH reduced the antiandrogenic
effect of BPA in human and mouse testes, whereas it potenti-
ated this effect in the rat. Thus, the use of basal conditions for
health risk assessment gives the highest degree of protection
for human health. Moreover, the results we obtained in basal,
but not in LH-stimulated, conditions are in agreement with
bibliographic data suggesting that low doses of BPA affect
fetal Leydig cell functions in human, but not rat, testes (see
‘‘BPA Affects Fetal Testis Development’’ section, above).
Consequently, we decided to assess the effect of BPS and
BPF with the use of the FeTA system in basal conditions
with human and mouse fetal testes.
BPS AND BPF ARE NOT SAFE ALTERNATIVES
TO BPA
Effect of BPS and BPF on Testosterone Secretion
and Comparison with BPA
Using the mouse FeTA model in basal conditions, we tested
BPF and BPS effects on testosterone secretion (Fig. 4A). We15
FIGURE 3
Effect of bisphenol A (BPA) on (A) basal and (B) LH-stimulated testosterone secretion by rat, mouse, and human fetal testes. Rat (14.5 days post-
conception [dpc]), mouse (12.5 dpc), and human (6.3–11.1 gestational weeks) fetal testes were culturedwith the use of the fetal testis assay system
as described in the legend to Figure 2. After 24 hours in control medium (D0), explants were cultured in the presence of vehicle alone (ethanol,
control explants) or BPA (CAS no. 80-05-7; Sigma; BPA-treated explants) for the three subsequent days (D1 to D3). BPA concentrations ranged
from 0.001 nmol/L to 10,000 nmol/L. Control and treated explants came from the contralateral testis of the same fetus (rat and mouse) or
from the same testis (human). From D1 to D3, the medium contained (A) no LH (basal secretion) or (B) 100 ng/mL LH from human pituitary
(R5,000 IU/mg; Sigma; LH-stimulated secretion). Control and BPA-treated explants were from the same mother. The daily amount of
testosterone secreted in the medium was measured by means of radioimmunoassay, and the values at D1–D3 were divided by the secretion at
D0 from the same sample to obtain relative values. Results are presented as the mean  SEM of n ratios of the relative secretion of the BPA-
treated explants to the relative secretion of the corresponding control explants. Rat: 7–12 fetuses (except for 0.001 nmol/L BPA in LH-
stimulated conditions, where n ¼ 4); mouse: 9–17 fetuses; human: 6–8 fetuses (except for 0.001 nmol/L BPA in basal and LH-stimulated
conditions, where n ¼ 4 and 5, respectively). *P<.05; **P<.01; ***P<.001 (compared with untreated controls by means of the Wilcoxon
nonparametric paired test). Basal values at D2 (A) are from N'Tumba-Byn et al. (58) completed with new data for 1,000 nmol/L BPA in human
and mouse testis explants.
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VIEWS AND REVIEWSfound that BPF showed the same dose-response curve as BPA
with a reduction in the amount of testosterone secreted by
mouse fetal testes starting from 1,000 nmol/L. BPS had
even a more potent inhibitory effect than BPA. Indeed,
100 nmol/L BPS signiﬁcantly reduced testosterone secretion
during the 3 days of treatment, whereas no change was
observed with 10 nmol/L and 100 nmol/L BPA.
With the use of the human FeTA model in basal condi-
tions (Fig. 4B), we ﬁrst conﬁrmed the nonmonotonic proﬁle
of the dose-response curve for BPA previously observed in
human fetal testes (58). Indeed, the inhibitory effect on testos-
terone secretion of 10 nmol/L BPA (i.e., the average BPA con-
centration found in human blood samples in most, but not all
studies) was higher than the effect of 100 nmol/L, whereas the
effect increased as a function of BPA concentration from 100
to 10,000 nmol/L. Similarly, BPS and BPF reduced the basal16testosterone secretion in cultured human fetal testes and
showed antiandrogenic effects already at 10 nmol/L with
nonmonotonic dose-response curves at days 1 and 2.
This is the ﬁrst report showing that BPS and BPF may be
harmful for one physiologic function in both humans and ro-
dents. Presently, there are no epidemiologic data on the link
between BPS or BPF exposure and human health effects.
Overall, there are very few data concerning the risk assess-
ment of BPS and BPF. BPS was reported to decrease testos-
terone production and Cyp17a and 17bhsd mRNA levels in
zebraﬁsh (81). However, no experimental study on in vivo
mammal exposure or in mammalian organ/primary cell cul-
tures has been published so far. The available data are all
issued from cell lines in culture. It was reported that the
capacities of BPS and BPF to activate estrogen receptors alpha
(ERa) and beta (ERb) are, respectively, 5- and 10-fold lowerVOL. 103 NO. 1 / JANUARY 2015
FIGURE 4
Comparative effects of bisphenols A (BPA), S (BPS), and F (BPF) on basal testosterone secretion by (A) mouse and (B) human fetal testes. Mouse
(12.5 days post- conception) or human (6.3–11.1 gestational weeks) fetal testes were cultured with the use of the fetal testis assay system as
described in the legend to Figure 2. After 24 hours in control medium (D0), explants were cultured in the presence of vehicle (control explants),
BPA, BPS (CAS no. 80-09-1) or BPF (CAS no. 620-92-8; all from Sigma) at concentrations ranging from 10 nmol/L to 10,000 nmol/L for the
three subsequent days (D1 to D3). As in Figure 3, control and treated explants were from the same fetus (mouse) or the same testis (human).
As in Figure 3, results are presented as mean  SEM of the relative secretion of treated explants divided by the relative secretion in the
corresponding control explants. Mouse: 9–17 fetuses; human: 6–10 fetuses. xP<.1; *P<.05; **P<.01; ***P<.001 (compared with untreated
explants by means of the Wilcoxon nonparametric paired test).
Eladak. BPS and BPF are not safe BPA alternatives. Fertil Steril 2015.
Fertility and Sterility®than that of BPA in the HELN cell line (82). However, it must
be noted that, although this result is important, its scope for
environmental health is limited because BPA does not prob-
ably physiologically act by directly binding to the classic
ERa and ERb (8). Indeed, its afﬁnity for these receptors is
very low (afﬁnity constant Kd of 0.2 and 0.04 mmol/L, respec-
tively) (83). Furthermore, the antiandrogenic effect of BPA is
maintained after ERa genetic invalidation, differently from
DES, suggesting that BPA effect is mediated by another recep-
tor (58). With the use of the human hepatoma cell line Hep3B,
it was reported that BPS could not reproduce various effects of
BPA, such as inhibition of the hypoxic response, intracellularVOL. 103 NO. 1 / JANUARY 2015lipid increase, pregnane X receptor activation, and changes in
the expression of many lipid metabolism genes (84, 85). The
E-screen test, an assay to determine the estrogenic activity
of chemical compounds with the use of the estrogen-
sensitive human breast cancer cell line MCF-7, showed that
BPA and BPF estrogenicity were similar, whereas BPS had a
weaker effect (82). In a rat pituitary cell line, cell proliferation
was activated only by fento-to nanomolar concentrations of
BPS and was reduced by these very low BPS concentrations in
the presence of E2 (86). BPF was less cytotoxic than BPA in the
HepG2 human hepatoblastoma cells; however, BPF had gen-
otoxic effects that were not observed with BPA (87). BPS17
FIGURE 5
Effect of 10,000 nmol/L bisphenol A (BPA), S (BPS), and F (BPF) on the
expression of Leydig cell–speciﬁc genes in mouse fetal testes. Testes
from 12.5-days-after-conception mouse fetuses were cultured with
the use of the fetal testis assay system. One testis was cultured in
basal medium with vehicle (ethanol, control testis) and the
contralateral testis in the presence of 10,000 nmol/L BPA, BPS, or
BPF for 3 days (treated testis). The procedure to measure gene
expression was previously described (58). Total RNA from a pool of
6–8 testes was extracted with the use of the RNeasy Micro-kit
(Qiagen), and 300 mg was reverse-transcribed with the use of the
High-Capacity cDNA Reverse Transcription kit (Applied Biosystems–
Life Technologies). Then, Taqman low-density array analysis was
performed on a 7900HT real-time polymerase chain reaction
system, and the expressions of six Leydig cell–speciﬁc genes were
quantiﬁed. Gene expressions were analyzed with the use of the
DDCt method and normalized with the use of the geometric mean
of two reference genes (Gapdh and 18S). Gene expressions in
treated gonads were calculated relative to the speciﬁc contralateral
control testis. Data are shown as individual values of three pools
and are the average log2 of the relative quantiﬁcation from each
experiment. No signiﬁcant differences were found between treated
and control testes with the use of the Wilcoxon nonparametric
paired test.
VIEWS AND REVIEWSshowed similar or more potent effects compared with BPA on
lipid metabolism in 3T3-L1 adipocytes (88), whereas BPF ef-
fect was lower than that of BPA on adiponectin production
and secretion (89). Finally, BPS and BPF reduced the steroido-
genic activity of the adrenocortical carcinoma cell line
H295 R, but their potencies were, respectively, 5- and 10-
fold lower than that of BPA (90). Collectively, these data
show that BPS and BPF often display BPA-like activity in
cell lines with weaker, equal, or higher potency than BPA, de-
pending on the model and the end points. It is therefore urgent
to assess their toxicity with the use of experimental models
that are closer to physiologic reality.
The impact of a bisphenol on human health depends not
only on its potential hazard, but also on the exposure level.
Because BPS and BPF uses are not regulated, it is difﬁcult to
list the consumables containing and leaching these com-
pounds. It is known that BPS is often used as a BPA alternative
in ‘‘BPA-free’’ thermal printing paper (91). There are few
quantitative data on BPS and BPF human exposure. In the
USA, the bisphenol analogues predominantly found in food-
stuff are BPA and BPF and they account for, respectively,
42% and 17% of all bisphenols (92). In a recent study, BPS
was detected in 81% of urine samples collected in the general
population in the USA and in various Asian countries (91, 93).
Concentrations ranged from 0.02 (limit of detection) to 21 ng/
mL (80 nmol/L), and the geometric mean was 0.17 ng/mL
(0.7 nmol/L). This varied among countries, and the highest
geometric means were observed in Japan and the USA. Thus,
the internal concentration of BPS is probably roughly
10-fold lower than that of BPA, but BPS human exposure
should largely increase if BPA is gradually replaced by BPS.
Furthermore, from the environmental health point of view,
one must consider the possibility of additive effects of the
various bisphenols.Eladak. BPS and BPF are not safe BPA alternatives. Fertil Steril 2015.Effect of BPA, BPS, and BPF on Fetal Leydig
Cell–speciﬁc Gene Expression
Finally, we compared the effects of 10,000 nmol/L BPA, BPS,
and BPF on the expression of fetal Leydig cell–speciﬁc genes
in 12.5-dpc fetal mouse testis explants (Fig. 5). BPA, BPS, and
BPF tended to reduce the expression of all key genes involved
in testosterone biosynthesis (Star, Hsd3b1, Cyp17a1), except
Cyp11a1, although statistical signiﬁcance was never reached
owing to experimental variability and the limited number of
samples. The three bisphenols also decreased (again not
signiﬁcantly) the expression of Lhcgr (the gene encoding
the LH/CG receptor). This is not in contradiction to the ﬁnding
that BPA effect on maximum LH-stimulated testosterone
secretion is weaker than that on basal secretion, because the
number of LH/CG receptors is not a limiting factor for maxi-
mally LH-stimulated testosterone secretion (66, 67). Finally,
Insl3 expression appeared also to be affected by exposure to
the three bisphenols, in agreement with INSL3 down-
regulation previously observed in human fetal testes incu-
bated with 108 mol/L BPA (58). Importantly, we conﬁrmed
by means of classic qPCR method that BPS and BPF exposure
decrease the expression of Insl3 by 43  3% and 44  2%,
respectively (P¼ .062 [Wilcoxon test]; n¼ 5; data not shown).18This is the ﬁrst comparison of BPA, BPS, and BPF effect
on the expression of genes involved in the steroidogenic
pathway and Leydig cells differentiation. Earlier data were
restricted to BPA and did not permit drawing clear conclu-
sions. BPA gavage led to a reduction in LH/CG receptor pro-
tein level in adult-type Leydig cells (94). Conversely, it did not
change the expression of Star, Cyp11a1, Hsd3b1, Cyp17a1,
and Lhcgr in mTCL1 cells (mouse Leydig tumor cells) (95),
but it reduced the expression of Cyp17a1 in rat adult Leydig
cells in culture (80)and in H295R human adrenocortical carci-
noma cells (96). Future studies should determine more pre-
cisely whether BPS and BPF activate similar pathways in
fetal testes and might thus have additive effects.CONCLUSION
This paper highlights the need of rigorous comparisons of
EDC hazards in human and rodent models in agreement
with our previous warning (56, 57).
It shows how BPA is again at the forefront of EDC
research because its ban or restriction has raised the ques-
tion of how to replace it. In this study, we used ourVOL. 103 NO. 1 / JANUARY 2015
Fertility and Sterility®in vitro organotypic culture system to conﬁrm that concen-
trations of BPA that are environmentally relevant according
to most (but not for all) biomonitoring studies, reduce the
basal androgenic activity of human fetal testis during a
crucial period for masculinization. We also observed that
rat and mouse fetal testes are at least 100-fold less sensitive
to BPA than human fetal testes in the same conditions. We
then demonstrated that in basal conditions (in which fetal
testes are most sensitive to BPA effects), BPS and BPF,
which are gradually replacing BPA, have antiandrogenic ef-
fects that are similar to those of BPA. This is the ﬁrst report
showing a harmful effect of BPS and BPF on a physiologic
function in humans and rodents. Because there would be no
value in trading one health hazard for another, we should
urgently focus on the human health risk assessment of
BPA substitutes.
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